EGFR and non-small cell lung carcinoma: In addition to brigatinib, Yong Jia's team found that the combination of the novel EGFR allosteric inhibitor EAI045, combined with cetuximab, has a significant effect on the L858R-T790M-C797S triple mutant but not on the ex19del mutant NSCLC cells (Figs. 3–4) [91].